ERYTECH's Lead AML Drug Flunks Phase II Test Post author:Sam Post published:December 7, 2017 Post category:BioPharma The study enrolled a total of 123 patients at 30 European sites. Source: BioSpace You Might Also Like Oramed Appoints As Chief Strategy Officer March 20, 2017 Maetrics Launches NEW Training Courses For 2017 February 16, 2017 Germany's Novaliq Sets Up U.S. Subsidiary in Cambridge, Massachusetts January 8, 2018
